Key information
In this course we discuss the early findings with regard to the kinetics of tumor cell death that lead to current approaches to the treatment of cancer. For the major classes of cytotoxic agents that are used in veterinary medicine we have a detailed discussion of the mechanisms of action and potential mechanisms leading to intrinsic and/or acquired resistance. We also discuss some of the concepts that underlie combination chemotherapy and finally, provide some examples of the link between pharmacokinetics and pharmacodynamics of some chemotherapy agents.
Learning Objectives
- Describe the kinetic basis of cancer drug therapy
- Describe determinants of intrinsic tumor cell sensitivity, specifically related to drug class and cell-intrinsic factors
- Describe putative mechanisms of action for anti-cancer agents used in veterinary medicine
- Describe key components driving efficacy of combination chemotherapy: dose intensity and effect of schedule
- List and provide examples of tumor cell resistance mechanisms for anti-cancer agents used in veterinary medicine: intrinsic resistance, acquired resistance and pharmacokinetic factors influencing dose-response relationship
- Describe the pharmacokinetic-pharmacodynamic relationships driving efficacy and toxicity for select drugs: carboplatin and doxorubicin
Presenter - Luke Wittenburg, DVM, PhD, DACVCP
- Assistant Professor, Developmental Cancer Therapeutics
- Surgical and Radiological Sciences
- Center for Companion Animal Health
The ACVIM has developed nine (9) Science of Veterinary Oncology (SOVO) online courses that are currently available and complimentary for ACVIM members with five (5) more in development and coming soon. These modules offer foundational building blocks of core knowledge areas pertaining to veterinary oncology and were developed based on the Job Task Analysis review performed in 2016. All modules are led by industry experts and each module is RACE-approved.
All Sessions:
- Cancer Bioenergetics - Douglass H. Thamm, VMD, DACVIM (Oncology)
- Cancer Stem Cells - Professor David Argyle, PhD and Lisa Pang, PhD
- Cell Signaling and Signal Transduction Inhibitors - Cheryl London, DVM, PhD, DACVIM (Oncology)
- Discovery and Evaluation of Anticancer Drugs - David Lowery, PhD
- Epigenetics of Cancer - Jeffrey Bryan, DVM, MS, Phd, DACVIM (Oncology)
- Genomic Instability - Kelly R. Hume, DVM, DACVIM (Oncology)
- Invasion and Metastasis - Robert B. Rebhun, DVM, PhD, DACVIM (Oncology)
- Pharmacology of Cancer Drugs and Resistance - Luke Wittenburg, DVM, PhD, DACVCP
- Tumor Microenvironment - Jamie Modiano, VMD, PhD
